| 31. |
- Lotz, Jannik, et al.
(författare)
-
Microservice Architectures for Advanced Driver Assistance Systems: A Case-Study
- 2019
-
Ingår i: Proceedings - 2019 IEEE International Conference on Software Architecture - Companion, ICSA-C 2019. ; , s. 45-52
-
Konferensbidrag (refereegranskat)abstract
- The technological advancements of recent years have steadily increased the complexity of vehicle-internal software systems, and the ongoing development towards autonomous driving will further aggravate this situation. This is leading to a level of complexity that is pushing the limits of existing vehicle software architectures and system designs. By changing the software structure to a service-based architecture, companies in other domains successfully managed the rising complexity and created a more agile and future-oriented development process. This paper presents a case-study investigating the feasibility and possible effects of changing the software architecture for a complex driver assistance function to a microservice architecture. The complete procedure is described, starting with the description of the software-environment and the corresponding requirements, followed by the implementation, and the final testing. In addition, this paper provides a high-level evaluation of the microservice architecture for the automotive use-case. The results show that microservice architectures can reduce complexity and time-consuming process steps and make the automotive software systems prepared for upcoming challenges as long as the principles of microservice architectures are carefully followed.
|
|
| 32. |
- Maccaferri, Nicolò, et al.
(författare)
-
Polarizability and magnetoplasmonic properties of magnetic general nanoellipsoids
- 2013
-
Ingår i: Optics Express. - : Optica Publishing Group. - 1094-4087. ; 21:8, s. 9875-9889
-
Tidskriftsartikel (refereegranskat)abstract
- An approach to compute the polarizability tensor of magnetic nanoparticles having general ellipsoidal shape is presented. We find a surprisingly excellent quantitative agreement between calculated and experimental magneto-optical spectra measured in the polar Kerr configuration from nickel nanodisks of large size (exceeding 100 nm) with circular and elliptical shape. In spite of its approximations and simplicity, the formalism presented here captures the essential physics of the interplay between magneto-optical activity and the plasmonic resonance of the individual particle. The results highlight the key role of the dynamic depolarization effects to account for the magneto-optical properties of plasmonic nanostructures.
|
|
| 33. |
- Maccaferri, Nicolò, et al.
(författare)
-
Tuning the Magneto-Optical Response of Nanosize Ferromagnetic Ni Disks Using the Phase of Localized Plasmons
- 2013
-
Ingår i: Physical Review Letters. - : American Physical Society. - 0031-9007 .- 1079-7114. ; 111:16
-
Tidskriftsartikel (refereegranskat)abstract
- We explore the influence of the phase of localized plasmon resonances on the magneto-optical activity of nanoferromagnets. We demonstrate that these systems can be described as two orthogonal damped oscillators coupled by the spin-orbit interaction. We prove that only the spin-orbit induced transverse plasmon plays an active role on the magneto-optical properties by controlling the relative amplitude and phase lag between the two oscillators. Our theoretical predictions are fully confirmed by magneto-optical Kerr effect and optical extinction measurements in nanostructures of different size and shape.
|
|
| 34. |
|
|
| 35. |
- Mondello, Stefania, et al.
(författare)
-
The Challenge of Mild Traumatic Brain Injury : Role of Biochemical Markers in Diagnosis of Brain Damage
- 2013
-
Ingår i: Medicinal research reviews (Print). - : John Wiley & Sons. - 0198-6325 .- 1098-1128. ; 34:3, s. 503-531
-
Forskningsöversikt (refereegranskat)abstract
- During the past decade there has been an increasing recognition of the incidence of mildtraumatic brain injury (mTBI) and a better understanding of the subtle neurological and cognitive deficitsthat may result from it. A substantial, albeit suboptimal, effort has been made to define diagnostic criteriafor mTBI and improve diagnostic accuracy. Thus, biomarkers that can accurately and objectively detectbrain injury after mTBI and, ideally, aid in clinical management are needed. In this review, we discuss thecurrent research on serum biomarkers for mTBI including their rationale and diagnostic performances.Sensitive and specific biomarkers reflecting brain injury can provide important information regardingTBI pathophysiology and serve as candidate markers for predicting abnormal computed tomographyfindings and/or the development of residual deficits in patients who sustain an mTBI. We also outline theroles of biomarkers in settings of specific interest including pediatric TBI, sports concussions and militaryinjuries, and provide perspectives on the validation of such markers for use in the clinic. Finally, emergingproteomics-based strategies for identifying novel markers will be discussed.
|
|
| 36. |
- Möller, Per Werner, et al.
(författare)
-
The Effects of Vasoconstriction And Volume Expansion on Veno-Arterial ECMO Flow
- 2019
-
Ingår i: Shock. - 1073-2322. ; 51:5, s. 650-658
-
Tidskriftsartikel (refereegranskat)abstract
- Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is gaining widespread use in the treatment of severe cardiorespiratory failure. Blood volume expansion is commonly used to increase ECMO flow (QECMO), with risk of positive fluid balance and worsening prognosis. We studied the effects of vasoconstriction on recruitment of blood volume as an alternative for increasing QECMO, based on the concepts of venous return.In a closed chest, centrally cannulated porcine preparation (n=9) in ventricular fibrillation and VA-ECMO with vented left atrium, mean systemic filling pressure (MSFP), and venous return driving pressure (VRdP) were determined in Euvolemia, during Vasoconstriction (norepinephrine 0.05, 0.125, and 0.2μg/kg/min) and after Volume Expansion (3 boluses of 10mL/kg Ringer's lactate). Maximum achievable QECMO was examined.Vasoconstriction and Volume Expansion both increased maximum achievable QECMO, delivery of oxygen (DO2), and MSFP, but right atrial pressure increased in parallel. VRdP did not change. The vascular elastance curve was shifted to the left by Vasoconstriction, with recruitment of stressed volume. It was shifted to the right by Volume Expansion with direct expansion of stressed volume. Volume Expansion decreased resistance to venous return and pump afterload.In a circulation completely dependent on ECMO support, maximum achievable flow directly depended on the vascular factors governing venous return-i.e., closing conditions, stressed vascular volume and the elastance and resistive properties of the vasculature. Both treatments increased maximum achievable ECMO flow at stable DO2, via increases in stressed volume by different mechanisms. Vascular resistance and pump afterload decreased with Volume Expansion.
|
|
| 37. |
- Oefner, Carolin M., et al.
(författare)
-
Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs
- 2012
-
Ingår i: Journal of Allergy and Clinical Immunology. - : Elsevier BV. - 1097-6825 .- 0091-6749. ; 129:6, s. 1647-1647
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Under inflammatory conditions, T cell-dependent (TD) protein antigens induce proinflammatory T-and B-cell responses. In contrast, tolerance induction by TD antigens without costimulation triggers the development of regulatory T cells. Under both conditions, IgG antibodies are generated, but whether they have different immunoregulatory functions remains elusive. Objective: It was shown recently that proinflammatory or anti-inflammatory effector functions of IgG molecules are determined by different Fc N-linked glycosylation patterns. We sought to examine the Fc glycosylation and anti-inflammatory quality of IgG molecules formed on TD tolerance induction. Methods: We administered chicken ovalbumin (OVA) with or without costimulus to mice and analyzed OVA-reactive IgG Fc glycosylation. The anti-inflammatory function of differentially glycosylated anti-OVA IgGs was further investigated in studies with dendritic cell cultures and in an in vivo model of allergic airway disease. Additionally, we analyzed the Fc glycosylation pattern of birch pollen-reactive serum IgGs after successful allergen-specific immunotherapy in patients. Results: Stimulation with TD antigens under inflammatory conditions induces plasma cells expressing low levels of alpha 2,6-sialyltransferase and producing desialylated IgGs. In contrast, plasma cells induced on tolerance induction did not downregulate alpha 2,6-sialyltransferase expression and secreted immunosuppressive sialylated IgGs that were sufficient to block antigen-specific T- and B-cell responses, dendritic cell maturation, and allergic airway inflammation. Importantly, successful specific immunotherapy in allergic patients also induced sialylated allergen-specific IgGs. Conclusions: Our data show a novel antigen-specific immunoregulatory mechanism mediated by anti-inflammatory sialylated IgGs that are formed on TD tolerance induction. These findings might help to develop novel antigen-specific therapies for the treatment of allergy and autoimmunity. (J Allergy Clin Immunol 2012;129:1647-55.)
|
|
| 38. |
- Osorio, Ana, et al.
(författare)
-
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
- 2014
-
Ingår i: PLoS Genetics. - : Public Library of Science (PLoS). - 1553-7404. ; 10:4
-
Tidskriftsartikel (refereegranskat)abstract
- Single Nucleotide Polymorphisms (SNPs) in genes involved in the DNA Base Excision Repair (BER) pathway could be associated with cancer risk in carriers of mutations in the high-penetrance susceptibility genes BRCA1 and BRCA2, given the relation of synthetic lethality that exists between one of the components of the BER pathway, PARP1 (poly ADP ribose polymerase), and both BRCA1 and BRCA2. In the present study, we have performed a comprehensive analysis of 18 genes involved in BER using a tagging SNP approach in a large series of BRCA1 and BRCA2 mutation carriers. 144 SNPs were analyzed in a two stage study involving 23,463 carriers from the CIMBA consortium (the Consortium of Investigators of Modifiers of BRCA1 and BRCA2). Eleven SNPs showed evidence of association with breast and/or ovarian cancer at p<0.05 in the combined analysis. Four of the five genes for which strongest evidence of association was observed were DNA glycosylases. The strongest evidence was for rs1466785 in the NEIL2 (endonuclease VIII-like 2) gene (HR: 1.09, 95% CI (1.03-1.16), p = 2.7×10-3) for association with breast cancer risk in BRCA2 mutation carriers, and rs2304277 in the OGG1 (8-guanine DNA glycosylase) gene, with ovarian cancer risk in BRCA1 mutation carriers (HR: 1.12 95%CI: 1.03-1.21, p = 4.8×10-3). DNA glycosylases involved in the first steps of the BER pathway may be associated with cancer risk in BRCA1/2 mutation carriers and should be more comprehensively studied.
|
|
| 39. |
- Ritscher, Amélie, et al.
(författare)
-
Zurich Statement on Future Actions on Per - and Polyfluoroalkyl Substances (PFASs)
- 2018
-
Ingår i: Journal of Environmental Health Perspectives. - 0091-6765 .- 1552-9924. ; 126:8
-
Tidskriftsartikel (refereegranskat)abstract
- Per - and polyfluoroalkyl substances (PFASs) are man-made chemicals that contain at least one perfluoroalkyl moiety, -CnF2n-. To date, over 4,000 unique PFASs have been used in technical applications and consumer products, and some of them have been detected globally in human and wildlife biomonitoring studies. Because of their extraordinary persistence, human and environmental exposure to PFASs will be a long-term source of concern. Some PFASs such as perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) have been investigated extensively and thus regulated, but for many other PFASs, knowledge about their current uses and hazards is still very limited or missing entirely. To address this problem and prepare an action plan for the assessment and management of PFASs in the coming years, a group of more than 50 international scientists and regulators held a two-day workshop in November, 2017. The group identified both the respective needs of and common goals shared by the scientific and the policy communities, made recommendations for cooperative actions, and outlined how the science-policy interface regarding PFASs can be strengthened using new approaches for assessing and managing highly persistent chemicals such as PFASs.
|
|
| 40. |
- Saussele, Susanne, et al.
(författare)
-
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI) : a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
- 2018
-
Ingår i: The Lancet Oncology. - : Elsevier. - 1470-2045 .- 1474-5488. ; 19:6, s. 747-757
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a prerequisite for TKI therapy discontinuation. We aimed to define precise conditions for stopping treatment. Methods: In this prospective, non-randomised trial, we enrolled patients with chronic myeloid leukaemia at 61 European centres in 11 countries. Eligible patients had chronic-phase chronic myeloid leukaemia, had received any TKI for at least 3 years (without treatment failure according to European LeukemiaNet [ELN] recommendations), and had a confirmed deep molecular response for at least 1 year. The primary endpoint was molecular relapse-free survival, defined by loss of major molecular response (MMR; >0·1% BCR-ABL1 on the International Scale) and assessed in all patients with at least one molecular result. Secondary endpoints were a prognostic analysis of factors affecting maintenance of MMR at 6 months in learning and validation samples and the cost impact of stopping TKI therapy. We considered loss of haematological response, progress to accelerated-phase chronic myeloid leukaemia, or blast crisis as serious adverse events. This study presents the results of the prespecified interim analysis, which was done after the 6-month molecular relapse-free survival status was known for 200 patients. The study is ongoing and is registered with ClinicalTrials.gov, number NCT01596114. Findings: Between May 30, 2012, and Dec 3, 2014, we assessed 868 patients with chronic myeloid leukaemia for eligibility, of whom 758 were enrolled. Median follow-up of the 755 patients evaluable for molecular response was 27 months (IQR 21–34). Molecular relapse-free survival for these patients was 61% (95% CI 57–64) at 6 months and 50% (46–54) at 24 months. Of these 755 patients, 371 (49%) lost MMR after TKI discontinuation, four (1%) died while in MMR for reasons unrelated to chronic myeloid leukaemia (myocardial infarction, lung cancer, renal cancer, and heart failure), and 13 (2%) restarted TKI therapy while in MMR. A further six (1%) patients died in chronic-phase chronic myeloid leukaemia after loss of MMR and re-initiation of TKI therapy for reasons unrelated to chronic myeloid leukaemia, and two (<1%) patients lost MMR despite restarting TKI therapy. In the prognostic analysis in 405 patients who received imatinib as first-line treatment (learning sample), longer treatment duration (odds ratio [OR] per year 1·14 [95% CI 1·05–1·23]; p=0·0010) and longer deep molecular response durations (1·13 [1·04–1·23]; p=0·0032) were associated with increasing probability of MMR maintenance at 6 months. The OR for deep molecular response duration was replicated in the validation sample consisting of 171 patients treated with any TKI as first-line treatment, although the association was not significant (1·13 [0·98–1·29]; p=0·08). TKI discontinuation was associated with substantial cost savings (an estimated €22 million). No serious adverse events were reported. Interpretation: Patients with chronic myeloid leukaemia who have achieved deep molecular responses have good molecular relapse-free survival. Such patients should be considered for TKI discontinuation, particularly those who have been in deep molecular response for a long time. Stopping treatment could spare patients from treatment-induced side-effects and reduce health expenditure. Funding: ELN Foundation and France National Cancer Institute.
|
|
